Back to Search
ALBERTO JIMENO, MD
MD
Internal Medicine Physician
NPI: 1629164900Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
A30730(CA)
Research & Publications (20)
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
PMID 19029951·Oncogene·2009
7-preclinical
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
PMID 19174553·Mol Cancer Ther·2009
7-preclinical
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
PMID 19124802·J Clin Oncol·2009
6-review
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
PMID 18955447·J Clin Oncol·2008
3-trial
Assessment of disease named entity recognition on a corpus of annotated sentences.
PMID 18426548·BMC Bioinformatics·2008
8-other
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
PMID 18245131·Ann Oncol·2008
3-trial
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
PMID 18208793·Clin Transl Oncol·2008
3-trial
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
PMID 17429623·Cancer Chemother Pharmacol·2008
3-trial
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
PMID 18757332·J Clin Oncol·2008
3-trial
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
PMID 18413752·Cancer Res·2008
7-preclinical
[Soft-tissue lesion of the head in a 9-month-old boy].
PMID 18358217·Enferm Infecc Microbiol Clin·2008
5-case
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
PMID 16425266·Pediatr Blood Cancer·2007
3-trial
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
PMID 17363501·Mol Cancer Ther·2007
4-observational
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.
PMID 17483439·Mol Cancer Ther·2007
7-preclinical
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
PMID 17342092·Br J Cancer·2007
7-preclinical
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
PMID 17045403·Biochim Biophys Acta·2006
6-review
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
PMID 17172427·Mol Cancer Ther·2006
3-trial
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
PMID 17169762·Clin Transl Oncol·2006
2-rct
Multitargeted therapy: can promiscuity be praised in an era of political correctness?
PMID 16843676·Crit Rev Oncol Hematol·2006
6-review
Atrasentan: a rationally designed targeted therapy for cancer.
PMID 16801993·Drugs Today (Barc)·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6061 WHITTIER BLVD
LOS ANGELES, CA 90022 - Phone
- (562) 725-1795
Quick Facts
- NPI
- 1629164900
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile